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Abstract
A microwave-assisted, continuous-flow organic synthesis (MACOS) protocol for the synthesis of
functionalized 1,2,5-thiadiazepane 1,1-dioxide library, utilizing a one-pot elimination and inter-/
intramolecular double aza-Michael addition strategy is reported. The optimized protocol in
MACOS was utilized for scale-out and further extended for library production using a
multicapillary flow reactor. A 50-member library of 1,2,5-thiadiazepane 1,1-dioxides was
prepared on a 100- to 300-mg scale with overall yields between 50 and 80% and over 90 % purity
determined by proton nuclear magnetic resonance (1H-NMR) spectroscopy.
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1. Introduction
Diversity-oriented synthesis (DOS) is an emerging field involving the synthesis of
combinatorial libraries of diverse small molecules for biological screening [1]. In contrast to
target-oriented synthesis that prepares a specific target compound, DOS is used to prepare
collections of structurally complex and diverse compounds from simple starting materials,
typically through the use of “split-pool” combinatorial chemistry [2]. DOS is used by
researchers in the pharmaceutical, agrochemical, and biotechnology industries to reduce the
time and cost associated with producing effective biologically active compounds.
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Sultams are useful heterocycles for medicinal chemistry applications, and a number has
demonstrated significant biological activity [3]. Methods that have been used to prepare
these cyclic sulfonamides include the intramolecular Diels–Alder reaction [4], cyclization of
aminosulfonyl chlorides [5], cycloadditions [6], radical cyclization [7], transition metal-
catalyzed approaches [8], and ring-closing metathesis (RCM) [9]. Moreover, we have
developed a variety of methodologies for the generation of five to eight-membered
annulated and non-annulated sultams through processes we have termed “Click-Click-
Cyclize” [10], “Click-Cyclize” [11], reagent-based DOS [12], “Click, Click, Cy-Click” [13],
and Heck, aza-Michael (HaM) strategies [14,15].
Our continued interest in the development of new methodologies to synthesize various
sultams libraries for high through put screening (HTS) [10–15] has prompted us to
investigate flow technology for parallel synthesis of functionalized 1,2,5-thiadiazepane 1,1-
dioxide scaffolds utilizing a microwave-assisted continuous-flow organic synthesis
(MACOS) platform. Previously, we reported on the MACOS preparation of 1,2,5-
thiadiazepane 1,1-dioxides and their scale-up [13]. Herein, we report the full details with the
production of a 50-member library utilizing multicapillary flow reactors (Scheme 1).
2. Results and Discussion
Inspired by our recently reported batch one-pot elimination/double aza-Michael (DaM)
strategy for the preparation of 1,2,5-thiadiazepane 1,1-dioxides [13], we decided to apply a
one-pot elimination and DaM strategy in MACOS to generate the desired scaffold
efficiently using a parallel multicapillary flow reactor.
Initial efforts focused on the preparation of a suitable Michael acceptor for the DaM
reaction. Towards this goal, racemic serine methyl ester (1) was protected with a tert-
butyldimethylsilyl (TBS) group [16] to provide a latent Michael acceptor, which would
become activated by the in situ β-elimination of the tert-butyldimethylsilyl hydroxide group
in the DaM step (Table 1). A “click” sulfonylation on 2 with commercially available 2-
chloroethanesulfonyl chloride provided secondary sulfonamide 3; the second Michael
accepting moiety was formed following β-elimination of HCl. DaM precursor 4 was
prepared after benzylation of 3 under mild conditions (Scheme 2). Utilizing this 3-step
protocol a collection of building blocks of tertiary vinyl sulfonamides on multigram scale
was assembled in excellent yield 75–90% with a variety of electron rich and poor benzyl
substituents (Scheme 2).
After successful preparation of the DaM building blocks, the next task was to optimize the
DaM reaction in MACOS for the scale-out preparation of these target molecules. As a
starting point, the best batch conditions were selected and applied in MACOS (Table 1,
Entry 1), which led to a mixture of DaM and mono aza-Michael (MaM) products. Heating to
a higher temperature in an effort to convert MaM products to DaM products led to a
complicated mixture. When DMF solvent was used with tBuOK as a base (flow rate 50 µL/
min at 150 °C), a complex mixture was produced in which there was no desired product
detected (Table 1, Entry 2). When the reaction was performed at 100 °C to avoid
decomposition, still, no desired product was observed (Table 1, Entry 3). We examined the
base and found that Et3N in DMF was ineffective leading only to starting material recovery
(Table 1, Entry 4). Use of DBU, which has intermediate basicity between tBuOK and Et3N,
provided the DaM product in 30% yield in DMF after screening a variety of parameters,
namely flow rate, power, and temperature (Table 1, Entries 5–9). In THF (Table 1, Entry
16), aza-Michael cyclization of the initially-formed Michael intermediate was curtailed
owing to the formation of the double addition product resulting from the intermolecular
addition of the secondary amine of this intermediate into a second molecule of 4. Similar
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reactivity was observed in MACOS studies on the intramolecular aza-Michael cyclization to
isoindolines [15]. When nBuOH was used as a solvent, the target DaMproducts were
produced, but they were always accompanied by transesterification products (Table 1, Entry
12). In an attempt to mitigate this side reaction, a 1:1 mixture of nBuOH and MeOH was
used, but this led to the same product mixture (Table 1, Entry 13). The transesterification
problem was ultimately overcome by switching solvent from nBuOH to iPrOH, which
provided the desired product in 55% yield (Table 1, Entry 14).
After the process was tested on a few examples at the milligram scale using the optimized
protocol (Table 1, Entry 14), we then set out to expand the scope of this reaction and scale-
out the quantity of the sultam products. This DaM MACOS strategy afforded the desired
sultams in excellent yields on gram scale, and the process could be run as long as desired to
make virtually any quantity [13]. With these results in hand, a parallel MACOS capillary
reactor was used to further streamline library synthesis. A variety of primary amines,
including linear, cyclic, and benzyl amine derivatives was chosen for the DaM reaction to
generate a 50-member library of 1,2,5-thiadiazepane 1,1-dioxides (Scheme 3, Figure 1).
3. Conclusion
We have developed a sequential elimination, double aza-Michael (DaM) cyclization
protocol in MACOS for the synthesis of 1,2,5-thiadiazepane 1,1-dioxides. This process
readily produces large quantities of product using a scale-out approach. Alternatively use of
a parallel MACOS capillary reactor facilitated the streamlined preparation of a 50-member
sultam library. This collection took approximately 2 weeks to complete, including
purification, and yielded 100–300 mg quantities of each product. These compounds have
been submitted to the NIH Molecular Library Small Molecule Repository (MLSMR) for
distribution within the MLSCN, which will allow for extensive biological screening.
4. Experimental
4.1. Microwave Irradiation Experiments
All MACOS experiments were performed in 1700 µm (ID) borosilicate capillaries, using a
single mode Biotage initiator operating at a frequency of 2.45 GHz with irradiation power
from 0 to 350 W. The capillary was fed reactants from Hamilton gastight syringes attached
to a Harvard 22 syringe pump pre-set to the desired flow rate. The system was connected to
a sealed collection vial, where a pressurized airline (75 psi) was attached to create back-
pressure. The temperatures reported were measured off the surface of the capillaries by the
IR sensor built into the microwave chamber. All reagents and solvents were purchased from
commercial sources and used without additional purification. Column chromatography
purifications were carried out using the flash technique on silica gel 60 (200–400 mesh). 1H-
and carbon nuclear magnetic resonance (13C-NMR) spectroscopy was run using a Bruker
Advance 400 MHz (400 MHz and 100 MHz, respectively). All 1H-NMR spectra were
calibrated to the signal from the residual proton of the deuterated chloroform solvent (7.26
ppm) while 13C-NMR spectra were calibrated to the middle carbon signal of the triplet for
deuterated chloroform (77.00 ppm). All compounds in this study have been isolated by silica
gel chromatography for the purpose of spectroscopic identification and to verify yield.
4.2. General Procedure: Synthesis of Sulfonamides 5A–5 F Utilizing MACOS Flow-Platform
At a time, four stock solutions containing the sulfonamide 4 (1.0 equiv.), DBU (1.2 equiv.),
and a different amine (1.2 equiv.) in iPrOH, (0.2–0.3 M) were prepared and loaded into four
Hamilton gastight syringes (3 mL). The tubing was primed with iPrOH, and the syringes
were connected to the reactor system with the aid of Microtight™ fittings. AHarvard 22
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syringe pumpwas set to deliver the reaction solution at a rate of 75 µL/min. These reactions
mixtures were simultaneously irradiated and collected in separate sealed vials. After
completion of the reaction, the internal pressure of the system was released by piercing the
septum with the needle after which the septum was removed and crude product was
analyzed directly by 1H-NMR spectroscopy. The solvent was removed from the reaction
mixture in vacuum by rotavap, and the crude products were purified directly by flash
column chromatography on silica gel (n-Pentane/EtOAc = 8:2) to afford products 5A–5F in
50–80% yield with over 90% purity determined by 1H-NMR spectroscopy.
4.2.1. Methyl 5-(cyclohexylmethyl)-2-(4-methylbenzyl)-1,2,5-thiadiazepane-3-
carboxylate 1,1-dioxide (5Aa)—Utilizing the general procedure, sultam 5Aa was
isolated in 76% yield (217 mg, 0.53 mmol) as a colorless solid; Mp 45–47 °C; Fourier
transform infrared spectrometry (FTIR) (thin film): 2923, 2847, 1745, 1453, 1325, 1134,
1067, 1005, 864, 762 cm−1; 1H NMR (300 MHz CDCl3) δ 7.27 (d, J=8.1 Hz, 2 H), 7.14 (d,
J=7.8 Hz, 2 H), 4.79 (d, J=15.0 Hz, 1 H), 4.25 (d, J=15.0, Hz, 1 H) 3.91 (dd, J=10.5, 6.6 Hz,
1 H), 3.57 (s, 3 H), 3.50 (dd, J=15.2, 10.5 Hz, 1 H), 3.56 (dd, J=6.9, 6.6 Hz, 1 H), 3.26–3.21
(m, 2 H), 3.01–2.96 (m, 2 H), 2.32 (s, 3 H), 2.16 (d, J=7.2 Hz, 2 H), 1.67–1.59 (m, 5 H),
1.28–1.14 (m, 4 H), 0.77 (m, 2 H) ppm; 13C NMR (75 MHz CDCl3) δ 170.5, 137.7, 132.7,
129.2, 129.1, 61.6, 56.8, 56.5, 55.0, 53.4, 52.2, 50.4, 36.1, 31.3, 31.3, 26.6, 25.9, 25.6, 21.1
ppm; HRMS (ESI): calculated for C21H33N2O4S (M+H): 409.2161; found 409.2161.
4.2.2. Methyl 5-(4-chlorobenzyl)-2-(4-methylbenzyl)-1,2,5-thiadiazepane-3-
carboxylate 1,1-dioxide (5Ab)—Utilizing the general procedure, sultam 5Ab was
isolated in 54% yield (164 mg, 0.38 mmol) as a colorless liquid; FTIR (thin film): 2949,
2918, 2838, 1739, 1321, 1138, 1085, 1009, 764 cm−1; 1H NMR (300 MHz CDCl3) δ 7.32–
7.21 (m, 6 H), 7.04 (d, J=8.4 Hz, 2 H), 4.94 (d, J=15.0 Hz, 1 H) 4.23 (d, J=15.0 Hz, 1 H),
3.86–3.81 (dd, J=10.5, 6.9 Hz, 1 H), 3.59 (s, 3 H), 3.53 (d, J=10.5, Hz, 2 H), 3.48 (d, J=10.2,
Hz, 1 H), 3.37 (dd, J=14.7, 6.9 Hz, 1 H), 3.25–321 (m, 2 H), 3.02–2.98 (m, 2 H), 2.39 (s, 3
H) ppm; 13C NMR (75 MHz CDCl3) δ 170.2, 138.0, 136.6, 133.1, 132.8, 129.6, 129.4,
128.6, 58.8, 56.7, 55.7, 55.1, 53.3, 52.3, 49.8 21.2 ppm; high resolution mass spectrometry
(HRMS) [electrospray ionization (ESI)] calculated for C21H26ClN2O4S (M+H) 437.1302;
found 437.1301.
4.2.3. Methyl 2-benzyl-5-(4-chlorobenzyl)-1,2,5-thiadiazepane-3-carboxylate
1,1-dioxide (5Ba)—Utilizing the general procedure, sultam 5Ba was isolated in 54% yield
(166 mg, 0.39 mmol) as a colorless solid; Mp 89–91 °C; FTIR (thin film) 2949, 2927, 2838,
1734, 1481, 1450, 1330, 1147, 1071, 1014, 773 cm−1; 1H NMR (300 MHz CDCl3) δ 7.44
(m, 5 H), 7.28 (d, J=8.4 Hz, 2 H), 7.06 (d, J=8.4 Hz, 2 H), 4.97 (d, J=15.0 Hz, 1 H), 4.30 (d,
J=15.0 Hz, 1 H), 3.89 (dd, J=10.5, 6.6 Hz, 1 H), 3.57 (s, 3 H), 3.55–3.45 (m, 3 H), 3.37 (dd,
J=14.7, 6.9 Hz, 1 H), 3.26 (m, 2 H), 3.02–2.98 (m, 2 H) ppm; 13C NMR (75 MHz CDCl3) δ
170.1, 136.6, 135.9, 133.2, 129.7, 129.3, 128.7, 128.2, 59.1, 57.0, 55.7, 55.1, 53.6, 52.3,
49.8 ppm; HRMS (ESI) calculated for C22H24ClN2O4S (M+H) 423.1145; found 423.1142.
4.2.4. Methyl 2-benzyl-5-(cyclohexylmethyl)-1,2,5-thiadiazepane-3-carboxylate
1,1-dioxide (5Bb)—Utilizing the general procedure, sultam 5Bb was isolated in 56% yield
(160 mg, 0.41 mmol) as a colorless crystalline solid; Mp 52–54 °C. FTIR (thin film): 2923,
2847, 1743, 1450, 1325, 1138, 1067, 1000, 867, 742 cm−1; 1H NMR (300 MHz CDCl3) δ
7.41–7.29 (m, 5 H), 4.82 (d, J=15.3 Hz, 1 H), 4.33 (d, J=15.0 Hz, 1 H), 3.96 (dd, J=10.5, 6.6
Hz, 1 H), 3.56 (s, 3 H), 3.48–3.43 (m, 1 H), 3.36–3.24 (m, 3 H), 3.03–2.99 (m, 2 H), 2.23 (d,
J=6.9 Hz, 2 H), 1.68 (m, 5 H), 1.34–1.16 (m, 4 H), 0.84–0.76 (m, 2 H) ppm. 13C NMR (75
MHz CDCl3) δ 170.4, 135.9, 129.1, 128.5, 128.0, 62.2, 57.1, 56.6, 55.0, 53.6, 52.2, 50.4,
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36.2, 31.4, 31.3, 26.6, 25.9; HRMS (ESI) calculated for C20H31N2O4S (M+H) 395.2005;
found 395.2003.
4.2.5. Methyl 2-(4-fluorobenzyl)-5-(4-methoxybenzyl)-1,2,5-thiadiazepane-3-
carboxylate 1,1-dioxide (5Ca)—Utilizing the general procedure, sultam 5Ca was
isolated in 52% yield (132 mg, 0.30 mmol) as a colorless solid; Mp 59–61 °C; FTIR (thin
film) 2954, 2914, 2834, 1734, 1601, 1512, 1321, 1245, 1134, 1080 cm−1; 1H NMR (300
MHz CDCl3) δ 7.24–7.38 (m, 2 H), 7.14–7.04 (m, 4 H), 6.88 (d, J=8.7 Hz, 2 H), 4.80 (d,
J=15.3 Hz, 1 H), 4.36 (d, J=15.3 Hz, 1 H), 3.93 (dd, J=10.5, 6.9 Hz, 1 H), 3.82 (s, 3 H), 3.69
(dd, J=12.9, 25.5 Hz, 2 H), 3.52 (s, 3 H), 3.47 (d, J=10.5 Hz, 1 H), 3.37 (dd, J=14.4, 6.6 Hz,
1 H), 3.23 (m, 2 H), 3.01 (m, 2 H) ppm; 13C NMR (75 MHz CDCl3) δ 170.0, 164.1 (d,
J=245.3 Hz), 159.1, 131.8 (d, J=3.0 Hz), 130.9 (d, J=8.3 Hz), 130.1 (d, J=27.0 Hz), 115.5 (d,
J=21.7 Hz), 113.9, 60.4, 57.6, 55.8, 55.2, 54.8, 52.9, 52.2, 49.5 ppm; HRMS (ESI)
calculated for C21H26FN2O5S (M +H) 437.1546; found 437.1545.
4.2.6. Methyl 5-(cyclohexylmethyl)-2-(4-fluorobenzyl)-1,2-thiazepane-3-
carboxylate 1,1-dioxide (5Cb)—Utilizing the general procedure, sultam 5Cb was
isolated in 56% yield (134 mg, 0.33 mmol) as a colorless solid; Mp 57–59 °C; FTIR (thin
film) 2927, 2847, 1739, 1597, 1508, 1450, 1321, 1218, 1138, 1005, 760 cm−1; 1H NMR
(300 MHz CDCl3) δ 7.39 (dd, J=8.4, 5.4 Hz, 2 H), 7.05 (dd, J=8.7, 8.7 Hz, 2 H), 4.72 (d,
J=15.3 Hz, 1 H), 4.34 (d, J=15.0 Hz, 1 H), 3.95 (dd, J=10.5, 6.9 Hz, 1 H), 3.55 (s, 3 H), 3.51
(dd, J=14.7, 10.5 Hz, 1 H), 3.35 (dd, J=14.7, 6.6 Hz, 1 H), 3.28 (m, 2 H), 3.02 (m, 2 H), 2.29
(d, J=7.2 Hz, 2 H), 1.70 (br d, J=3.6 Hz, 5 H), 1.34–1.14 (m, 4 H), 0.86 (m, 2 H) ppm; 13C
NMR (75 MHz CDCl3) δ 170.2, 164.1 (d, J=245.3 Hz), 131.8 (d, J=3.0 Hz), 130.8 (d, J=8.3
Hz), 115.5 (d, J=21.8 Hz), 62.9, 57.4, 56.7, 54.9, 52.9, 52.2, 50.4, 36.4, 31.5, 31.4, 26.6,
25.9 ppm; HRMS (ESI): calculated for C20H29FN2O4S 412.1832; 412.1830.
4.2.7. Methyl 2-(4-bromobenzyl)-5-(4-bromophenethyl)-1,2,5-thiadiazepane-3-
carboxylate 1,1-dioxide (5 Da)—Utilizing the general procedure, sultam 5 Da was
isolated in 51% yield (172 mg, 0.31 mmol) as a colorless liquid; FTIR (thin film) 2927,
2842, 1734, 1489, 1329, 1138, 1066, 1004, 761 cm−1; 1H NMR (300 MHz CDCl3) δ 7.46
(dd, J=8.4, 2.4 Hz, 4 H), 7.23 (d, J=8.1 Hz, 2 H), 7.05 (d, J=8.1 Hz, 2 H), 4.37 (d, J=15.3
Hz, 1 H), 4.33 (d, J=15.3 Hz, 1 H), 3.91 (dd, J=10.2, 6.9 Hz, 1 H), 3.54 (s, 3 H), 3.47–3.39
(m, 2 H), 3.24 (m, 2 H), 3.07 (m, 2 H), 2.86–2.81 (m, 2 H), 2.73 (d, J=6.9 Hz, 2 H) ppm; 13C
NMR (75 MHz CDCl3) δ 169.9, 138.4, 135.0, 131.6, 131.5, 130.4, 130.3, 121.9, 120.1, 57.9,
57.8, 56.2, 54.3, 53.1, 52.3, 50.0, 33.7 ppm; HRMS (ESI): calculated for C21H25Br2N2O4S
(M+H) 561.3072; found 561.3061.
4.2.8. Methyl 2-(4-bromobenzyl)-5-(cyclohexylmethyl)-1,2,5-thiadiazepane-3-
carboxylate 1,1-dioxide (5Db)—Utilizing the general procedure, sultam 5Db was
isolated in 63% yield (180 mg, 0.38 mmol) as a colorless liquid; FTIR (thin film) 2927,
2847, 1752, 1494, 1450, 1325, 1258, 1143, 1071, 1009, 760 cm−1; 1H NMR (300 MHz
CDCl3) δ 7.47 (d, J=8.4 Hz, 2 H), 7.29 (d, J=8.4 Hz, 2 H), 4.70 (d, J=15.3 Hz, 1 H), 4.30 (d,
J=15.3 Hz, 1 H), 3.94 (dd, J=10.5, 6.6 Hz, 1 H), 3.55 (s, 3 H), 3.48 (dd, J=14.7, 10.5 Hz, 1
H), 3.34 (dd, J=14.7, 6.6 Hz, 1 H), 3.29 (m, 2 H), 3.00 (m, 2 H), 2.28 (d, J=6.9 Hz, 2 H),
1.69 (m, 5 H), 1.36–1.16 (m, 4 H), 0.86 (m, 2 H) ppm; 13C NMR (75 MHz CDCl3) δ 170.1,
135.1, 131.6, 130.6, 121.9, 63.0, 57.6, 56.7, 54.8, 53.0, 52.3, 50.4, 36.3, 31.5, 31.4, 26.6,
25.9 ppm; HRMS (ESI): calculated for C20H30BrN2O4S (M+H) 473.1110; found 473.1109.
4.2.9. Methyl 5-(cyclohexylmethyl)-2-(3-(methoxycarbonyl)benzyl)-1,2,5-
thiadiazepane-3-carboxylate 1,1-dioxide (5Ea)—Utilizing the general procedure,
sultam 5Ea was isolated in 64% yield (184 mg, 0.41 mmol) as a colorless liquid; FTIR (thin
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film) 2923, 2847, 1730, 1445, 1330, 1285, 1209, 1014, 740 cm−1; 1H NMR (300 MHz
CDCl3) δ 7.98 (d, J=1.5 Hz, 2 H), 7.94 (m, 1 H), 7.64 (t, J=7.8 Hz, 1 H), 4.76- (d, J=15.3
Hz, 1 H), 4.30 (d, J=15.3 Hz, 1 H), 3.93 (m, 1 H), 3.90 (s, 3 H), 3.52 (s, 3 H), 3.48 (dd,
J=14.7, 10.5 Hz, 1 H), 3.34 (dd, J =14.7, 6.9 Hz, 1 H), 3.26 (m, 2 H), 3.00 (m, 2 H), 2.28 (m,
2 H), 1.66 (m, 5 H), 1.34–1.08 (m, 4 H), .82–0.75 (m, 2 H) ppm; 13C NMR (75 MHz
CDCl3) δ 170.1, 166.6, 136.5, 133.6, 130.3, 129.7, 129.2, 128.6, 62.6, 57.5, 56.6, 54.8, 53.4,
52.2, 52.2, 50.4, 36.3, 31.4, 31.3, 26.6, 25.9, 25.8 ppm; HRMS (ESI) calculated for
C22H33N2O6S (M+H) 453.2059; found 453.2057.
4.2.10. Methyl 5-(4-chlorobenzyl)-2-(3-(methoxycarbonyl)benzyl)-1,2,5-
thiadiazepane-3-carboxylate 1,1-dioxide (5Eb)—Utilizing the general procedure,
sultam 5Eb was isolated in 57% yield (174 mg, 0.36 mmol) as a colorless liquid; FTIR (thin
film) 2963, 2927, 2851, 1726, 1427, 1334, 1289, 1209, 1143, 1009, 738 cm−1; 1H NMR
(300 MHz CDCl3) δ 8.05 (d, J =8.4 Hz, 2 H), 7.70 (d, J=7.8 Hz, 1 H), 7.51 (t, J=7.8 Hz, 1
H), 7.29 (d, J=8.4 Hz, 2 H), 7.12 (d, J=8.4 Hz, 2 H), 4.90 (d, J=15.3 Hz, 1 H), 4.48 (d,
J=15.3 Hz, 1 H), 3.95 (s, 3 H), 3.87 (dd, J=10.5, 6.9 Hz, 1 H), 3.68 (d, J=7.8 Hz, 2 H), 3.54
(s, 3 H), 3.51 (dd, J=14.4, 10.5 Hz, 1 H), 3.36 (dd, J=14.7, 6.6 Hz, 1 H), 3.25 (m, 2 H), 3.02
(m, 2 H) ppm; 13C NMR (75 MHz CDCl3) δ 169.9, 166.6, 136.6, 136.5, 133.7, 133.3, 130.5,
129.9, 129.7, 129.3, 128.8, 128.7, 60.1, 57.6, 56.0, 54.7, 53.4, 52.3, 49.9 ppm; HRMS (ESI)
calculated for C22H26ClN2O6S (M+H) 481.1200; found 481.1180.
4.2.11. Methyl 2-(3-cyanobenzyl)-5-(cyclohexylmethyl)-1,2,5-thiadiazepane-3-
carboxylate 1,1-dioxide (5Fa)—Utilizing the general procedure, sultam 5Fa was
isolated in 63% yield (180 mg, 0.43 mmol) as a colorless liquid; FTIR (thin film) 2923,
2851, 1752, 1454, 1338, 1267, 1143, 1005, 760 cm−1; 1H NMR (300 MHz CDCl3) δ 7.72
(d, J=6.0 Hz, 2 H), 7.62 (d, J=7.5 Hz, 1 H), 7.50 (m, 1 H), 4.71 (d, J=15.9 Hz, 1 H), 4.44 (d,
J=15.6 Hz, 1 H), 4.03 (dd, J=10.2, 6.6 Hz, 1 H), 3.55 (s, 3 H), 3.49 (dd, J=14.4, 10.5 Hz, 1
H), 3.35 (d, J=6.6 Hz, 1 H), 3.29 (m, 2 H), 3.03 (m, 2 H), 2.39 (m, 2 H), 1.77 (m, 5 H),
1.39–1.18 (m, 4 H), 0.91–0.85 (m, 2 H) ppm; 13C NMR (75MHz CDCl3) δ 169.8, 138.0,
133.1, 132.0, 131.5, 129.3, 118.5, 112.5, 63.9, 58.2, 56.8, 54.7, 52.8, 52.3, 50.3, 36.5, 33.5,
31.6, 31.4, 26.6, 25.9 ppm; HRMS (ESI) calculated for C21H30N3O4S (M+H) 420.1957;
found 420.1956.
4.2.12. Methyl 5-benzyl-2-(3-cyanobenzyl)-1,2,5-thiadiazepane-3-carboxylate
1,1-dioxide (5Fb)—Utilizing the general procedure, sultam 5Fb was isolated in 57% yield
(160 mg, 0.39 mmol) as a colorless liquid; FTIR (thin film) 2949, 2927, 2838, 1748, 1427,
1334, 1138, 1076, 1005, 747, 702 cm−1; 1H NMR (300 MHz CDCl3) δ 7.72 (d, J=7.5 Hz, 2
H), 7.63 (d, J=7.8 Hz, 1 H), 7.51 (dd, J=7.5, 8.1 Hz, 1 H), 7.40–7.27 (m, 5 H), 4.76 (d,
J=15.9 Hz, 1 H), 4.46 (d, J=15.6 Hz, 1 H), 3.99 (dd, J=10.2, 6.9 Hz, 1 H), 3.83 (q, J=13.2
Hz, 2 H), 3.51 (s, 3 H), 4.71 (d, J=10.5 Hz, 1 H), 3.38 (dd, J=14.1, 6.9 Hz, 1 H), 3.26 (m, 2
H), 3.09–2.98 (m, 2 H) ppm; 13C NMR (75 MHz CDCl3) δ 169.6, 138.0, 138.0, 133.1,
132.0, 131.5, 129.3, 128.7, 128.6, 127.8, 118.5, 112.5, 61.9, 58.3, 56.1, 54.5, 52.7, 52.3,
49.6 ppm; HRMS (ESI) calculated for C21H24N3O4S (M+H) 414.1488; found 414.1487.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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1,2,5-thiadiazepane 1,1-dioxide library via MACOS
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One-pot elimination and double aza-Michael (DaM) strategy in flow
Ullah et al. Page 10














Preparation of double aza-Michael precursors
Ullah et al. Page 11














Synthesis of 1,2,5-thiadiazepane 1,1-dioxide library via MACOS using multi-capillary flow
reactor. (A) Schematic of the parallel, capillary multireactor system. (B) Photograph of the
parallel, capillary multireactor system
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